- Home
- PGRE vs OPK Comparison
PGRE vs OPK Comparison
Compare PGRE & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- OPK
- Stock Information
- Founded
- PGRE 1978
- OPK 2007
- Country
- PGRE United States
- OPK United States
- Employees
- PGRE N/A
- OPK N/A
- Industry
- PGRE Real Estate Investment Trusts
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- OPK Health Care
- Exchange
- PGRE Nasdaq
- OPK Nasdaq
- Market Cap
- PGRE 1.4B
- OPK 1.1B
- IPO Year
- PGRE 2014
- OPK 1995
- Fundamental
- Price
- PGRE $6.38
- OPK $1.35
- Analyst Decision
- PGRE Hold
- OPK Buy
- Analyst Count
- PGRE 4
- OPK 4
- Target Price
- PGRE $5.63
- OPK $2.75
- AVG Volume (30 Days)
- PGRE 3.8M
- OPK 3.1M
- Earning Date
- PGRE 07-30-2025
- OPK 08-06-2025
- Dividend Yield
- PGRE N/A
- OPK N/A
- EPS Growth
- PGRE N/A
- OPK N/A
- EPS
- PGRE N/A
- OPK N/A
- Revenue
- PGRE $711,729,000.00
- OPK $689,408,000.00
- Revenue This Year
- PGRE $1.41
- OPK N/A
- Revenue Next Year
- PGRE N/A
- OPK $6.98
- P/E Ratio
- PGRE N/A
- OPK N/A
- Revenue Growth
- PGRE 49.28
- OPK N/A
- 52 Week Low
- PGRE $3.75
- OPK $1.21
- 52 Week High
- PGRE $6.89
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- PGRE 54.98
- OPK 59.19
- Support Level
- PGRE $5.96
- OPK $1.33
- Resistance Level
- PGRE $6.89
- OPK $1.42
- Average True Range (ATR)
- PGRE 0.20
- OPK 0.04
- MACD
- PGRE -0.01
- OPK 0.01
- Stochastic Oscillator
- PGRE 51.61
- OPK 70.83
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.